

TABLE OF CONTENTS

PART I

PREFACE	<i>xiii</i>
CHAPTER 1 NOVELTY	1
I. INTRODUCTION	1
II. INTRODUCING NOVELTY	1
II.1. The Concept of Novelty.....	1
II.2. Absolute and Relative Novelty.....	2
II.3. Disclosure Issue in Novelty.....	4
II.4. Destroying Novelty	5
II.5. Grace Period.....	16
II.6. Guidelines for Examining Novelty	21
III. NOVELTY IN INTERNATIONAL AGREEMENTS	25
III.1. Novelty with Reference to the Agreement on Trade- Related Aspects of Intellectual Property Rights (TRIPS)	25
III.2. Novelty under the Patent Law Treaty (PLT) and the Draft Substantive Patent Law Treaty (SPLT).....	26
IV. SOME NOVELTY ISSUES IN PHARMACEUTICAL PATENTS	27
V. CONCLUSION AND RECOMMENDATIONS	38

CHAPTER 2	INVENTIVE STEP	39
I.	DEFINING THE CONCEPT	39
	I.1. Definition	39
II.	WHAT ARE THE PUBLIC HEALTH ISSUES IMPLICATED?	40
	II.1. Special Concerns with Pharmaceuticals and Inventive Step: The Use of Known Elements and Methodologies	41
III.	THE AGREEMENT ON TRADE-RELATED ASPECTS OF INTELLECTUAL PROPERTY RIGHTS (TRIPS)	43
	III.1. What are the TRIPS Requirements?	43
	III.2. What are the TRIPS Flexibilities?	44
IV.	WHAT ARE THE EXISTING POLICY APPROACHES?	44
	IV.1. The United States	48
	IV.2. The European Patent Office (EPO)	62
V.	THE SITUATION IN DEVELOPING COUNTRIES	70
	V.1. Example of Text and Language from Developing Countries	71
VI.	CONCLUSIONS AND RECOMMENDATIONS	74
CHAPTER 3	INDUSTRIAL APPLICABILITY/UTILITY	81
I.	INTRODUCTION	81
II.	INDUSTRIAL APPLICABILITY AND UTILITY	84
III.	TECHNICAL EFFECT UNDER EUROPEAN LAW	87
IV.	UTILITY IN US LAW AND PRACTICE	89
	IV.1. Enablement, Utility and Section 112	97
	IV.2. Proof and the Issue of More than One Utility	101
V.	INDUSTRIAL APPLICABILITY IN EUROPE	106

VI.	CONCLUSIONS AND RECOMMENDATIONS.....	108
-----	--------------------------------------	-----

**CHAPTER 4 THERAPEUTIC, SURGICAL AND
DIAGNOSTIC METHODS..... 109**

I.	INTRODUCTION.....	109
II.	THE RATIONALE FOR THE EXCLUSION OF THERAPEUTIC, SURGICAL AND DIAGNOSTIC METHODS	111
III.	THE SCOPE OF THE EXCLUSION.....	115
IV.	THE PATENTING OF A NEW THERAPEUTIC EFFECT	115
V.	CONCLUSION	117

CHAPTER 5 SECOND INDICATIONS..... 119

I.	DEFINING THE CONCEPT.....	119
	I.1. Definitions.....	119
	I.2. History of the Concept.....	126
II.	WHAT ARE THE PUBLIC HEALTH ISSUES IMPLICATED?	128
	II.1. Reduction of Access	128
	II.2. Biopiracy.....	129
	II.3. Promotion of Traditional Medicine	129
III.	THE AGREEMENT ON TRADE-RELATED ASPECTS OF INTELLECTUAL PROPERTY RIGHTS (TRIPS)	130
	III.1. What are the TRIPS Requirements?.....	130
	III.2. What are the TRIPS Flexibilities?.....	130
IV.	WHAT ARE THE EXISTING POLICY APPROACHES?.....	131
	IV.1. Options on New Uses: Advantages and Disadvantages.....	132

IV.2. The United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO): Advantages and Disadvantages	136
V. THE SITUATION IN DEVELOPING COUNTRIES	146
V.1. Countries that Specifically Exclude New Uses	147
V.2. Countries that Specifically Allow New Uses	151
VI. CONCLUSIONS AND RECOMMENDATIONS.....	153
BIBLIOGRAPHY	167

LIST OF BOXES

Box 1 Amgen/Erythropoietin	30
Box 2 Pfizer/Amlodipine	33

LIST OF ANNEXES AND APPENDICES

Annex I Model Regulations and Guidelines on Inventive Step.....	76
Appendix I Table of Developing Country Policies on Second Indications.....	154

PART II

CHAPTER 6 SUBSTANCES OCCURRING IN NATURE	173
I. INTRODUCTION.....	173
II. DEFINING A PRODUCT OF NATURE	173

III.	THE CONCEPT OF INVENTION AND THE PRODUCTS OF NATURE DOCTRINE.....	175
	III.1. The Doctrine in the United States	179
	III.2. The Doctrine in Europe	182
	III.3. Implications	183
IV.	CONCLUSIONS	188
 CHAPTER 7 FUNCTIONAL CLAIMS		189
I.	DEFINING THE CONCEPT.....	189
	I.1. Identifying the Outer Boundaries.....	189
II.	WHAT ARE THE PUBLIC HEALTH ISSUES IMPLICATED?	190
	II.1. Reduction of Access	190
III.	THE AGREEMENT ON TRADE-RELATED ASPECTS OF INTELLECTUAL PROPERTY RIGHTS (TRIPS)	193
	III.1 What are the TRIPS Requirements?.....	193
IV.	WHAT ARE THE EXISTING POLICY APPROACHES?.....	193
	IV.1. The European Patent Office (EPO).....	194
	IV.2. The United States Patent and Trademark Office (USPTO).....	198
V.	THE SITUATION IN DEVELOPING COUNTRIES	203
VI.	CONCLUSIONS AND RECOMMENDATIONS.....	205
 CHAPTER 8 ENABLING DISCLOSURE.....		207
I.	INTRODUCTION.....	207
	I.1. Meaning of ‘Enabling Disclosure’	208
II.	SUFFICIENT DISCLOSURE IN PRACTICE.....	212
	II.1. The Issue of Sufficient Enablement.....	212
	II.2. The Issue of the Person Skilled in the Art.....	220

III.	ENABLING DISCLOSURE IN THE LATEST TECHNOLOGY	227
III.1.	Facilitating Enabling Disclosure in Patents on Micro-organisms.....	227
IV.	LATEST LEGAL DEVELOPMENTS	229
IV.1.	The Enablement Issue in the Substantive Patent Law Treaty (SPLT)	229
IV.2.	Reform of Patent Law in the USA: The Issue of Enabling Disclosure.....	231
V.	CONCLUSION AND RECOMMENDATIONS	232
 CHAPTER 9 MARKUSH CLAIMS.....		235
I.	INTRODUCTION.....	235
II.	MARKUSH CLAIMS IN EUROPE AND THE USA.....	237
III.	CONCLUSION	240
 CHAPTER 10 SELECTION PATENTS		243
I.	INTRODUCTION.....	243
II.	EVOLUTION OF PRACTICES ON SELECTION INVENTION.....	245
III.	CONCLUSION	252
 CHAPTER 11 PRODUCT-BY-PROCESS CLAIMS.....		253
I.	INTRODUCTION.....	253
II.	PRODUCT-BY-PROCESS PATENTS IN THE USA.....	256

II.1. Admissibility of PPCs.....	256
II.2. Infringement.....	265
II.3. PPCs and Drug Registration.....	272
III. PRODUCT-BY-PROCESS PATENTS IN EUROPE	273
IV. PRODUCT-BY-PROCESS CLAIMS IN JAPAN.....	276
V. CONCLUSIONS AND RECOMMENDATIONS.....	277
BIBLIOGRAPHY	281

LIST OF BOXES AND FIGURES

Box 1 <i>No Fume v. Pitchford</i>	213
Box 2 <i>WL Gore and Associates v. Garlock Inc.</i>	215
Box 3 <i>Biogen v. Medeva</i>	219
Box 4 <i>Kirin Amgen Inc. & Others v. Avantis & Others</i>	224
Box 5 <i>Kirin Amgen Inc. v. Chugai Pharmaceutical Co. Ltd.</i>	225
Box 6 Article 10: Enabling Disclosure SCP/10/4.....	230
Box 7 Markush Claim Example	237
Figure 1 Genuine Selection Invention	244
Figure 2 Non-Genuine Selection Invention	244

LIST OF TABLES

Table of Legislative, Regulatory and Examination Guideline Approaches	203
---	-----